Tscan Therapeutics Inc’s recent filing unveils that its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $4114.0 on Nov 15 ’24. In the deal valued at $4.34 per share,947 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 5,225,547 shares worth roughly $17.4 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Klencke Barbara bought 5,000 shares, generating $26,450 in total proceeds. Upon buying the shares at $5.29, the Director now owns 45,000 shares.
Before that, Klencke Barbara bought 5,000 shares. Tscan Therapeutics Inc shares valued at $28,450 were divested by the Director at a price of $5.69 per share. As a result of the transaction, Klencke Barbara now holds 35,000 shares, worth roughly $0.12 million.
BTIG Research initiated its Tscan Therapeutics Inc [TCRX] rating to a Buy in a research note published on May 16, 2024; the price target was $12. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Wedbush began covering TCRX with “an Outperform” recommendation on June 22, 2023.
Price Performance Review of TCRX
On Tuesday, Tscan Therapeutics Inc [NASDAQ:TCRX] saw its stock fall -28.23% to $3.33. Over the last five days, the stock has lost -25.84%. Tscan Therapeutics Inc shares have fallen nearly -42.88% since the year began. Nevertheless, the stocks have fallen -49.24% over the past one year. While a 52-week high of $9.69 was reached on 05/21/24, a 52-week low of $3.92 was recorded on 12/10/24. SMA at 50 days reached $4.96, while 200 days put it at $6.47.
Levels Of Support And Resistance For TCRX Stock
The 24-hour chart illustrates a support level at 2.78, which if violated will result in even more drops to 2.24. On the upside, there is a resistance level at 4.29. A further resistance level may holdings at 5.26. The Relative Strength Index (RSI) on the 14-day chart is 30.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.53%. Stochastics %K at 44.65% indicates the stock is a holding.
How much short interest is there in Tscan Therapeutics Inc?
A steep rise in short interest was recorded in Tscan Therapeutics Inc stocks on 2024-11-29, growing by 0.15 million shares to a total of 2.32 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 2.16 million shares. There was a rise of 6.61%, which implies that there is a positive sentiment for the stock.
